Open AccessA case of insulinoma with hypoglycemia that was better managed with lanreotide than octreotide
Author(s) -
Yamaoka Keiko,
Nagashima Shuichi,
Okada Nobukazu,
Sawayama Nagisa,
Saito Shinsuke,
Takahashi Manabu,
Okada Kenta,
Endo Kazuhiro,
Koizumi Masaru,
Sasanuma Hideki,
Ebihara Ken,
Kasajima Atsuko,
Fukushima Noriyoshi,
Sata Naohiro,
Ishibashi Shun
Publication year - 2021
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.4118
Subject(s) - lanreotide , insulinoma , octreotide , medicine , hypoglycemia , somatostatin , endocrinology , gastroenterology , insulin , acromegaly , growth hormone , hormone
Long‐acting somatostatin analogs, including lanreotide slow release (LAN‐SR) and octreotide long‐acting release (OCT‐LAR), can improve hypoglycemia in insulinoma. LAN‐SR may be more beneficial in some patients with insulinoma than OCT‐LAR.